379 related articles for article (PubMed ID: 32733190)
1. Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions.
Dierssen M; Fructuoso M; Martínez de Lagrán M; Perluigi M; Barone E
Front Neurosci; 2020; 14():670. PubMed ID: 32733190
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome.
Lanzillotta C; Tramutola A; Di Giacomo G; Marini F; Butterfield DA; Di Domenico F; Perluigi M; Barone E
Free Radic Biol Med; 2021 Mar; 165():152-170. PubMed ID: 33516914
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
4. Cell models for Down syndrome-Alzheimer's disease research.
Wu Y; West NR; Bhattacharyya A; Wiseman FK
Neuronal Signal; 2022 Apr; 6(1):NS20210054. PubMed ID: 35449591
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets.
Izzo A; Mollo N; Nitti M; Paladino S; Calì G; Genesio R; Bonfiglio F; Cicatiello R; Barbato M; Sarnataro V; Conti A; Nitsch L
Mol Med; 2018 Mar; 24(1):2. PubMed ID: 30134785
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
7. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease.
Coskun P; Helguera P; Nemati Z; Bohannan RC; Thomas J; Samuel SE; Argueta J; Doran E; Wallace DC; Lott IT; Busciglio J
J Alzheimers Dis; 2017; 55(2):737-748. PubMed ID: 27802222
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.
Perluigi M; Butterfield DA
Curr Gerontol Geriatr Res; 2012; 2012():724904. PubMed ID: 22203843
[TBL] [Abstract][Full Text] [Related]
10. New Molecular and Organelle Alterations Linked to Down Syndrome Heart Disease.
Venegas-Zamora L; Bravo-Acuña F; Sigcho F; Gomez W; Bustamante-Salazar J; Pedrozo Z; Parra V
Front Genet; 2021; 12():792231. PubMed ID: 35126461
[TBL] [Abstract][Full Text] [Related]
11. Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles.
Perluigi M; Picca A; Montanari E; Calvani R; Marini F; Matassa R; Tramutola A; Villani A; Familiari G; Domenico FD; Butterfield DA; Oh KJ; Marzetti E; Valentini D; Barone E
Alzheimers Dement; 2022 Aug; 18(8):1498-1510. PubMed ID: 34812584
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial Dysfunction in Down Syndrome: From Pathology to Therapy.
Tan KL; Lee HC; Cheah PS; Ling KH
Neuroscience; 2023 Feb; 511():1-12. PubMed ID: 36496187
[TBL] [Abstract][Full Text] [Related]
13. Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society.
Delabar JM; Allinquant B; Bianchi D; Blumenthal T; Dekker A; Edgin J; O'Bryan J; Dierssen M; Potier MC; Wiseman F; Guedj F; Créau N; Reeves R; Gardiner K; Busciglio J
Mol Syndromol; 2016 Oct; 7(5):251-261. PubMed ID: 27867340
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer's Disease-like Neuropathology in a Mouse Model for Down Syndrome.
Tramutola A; Lanzillotta S; Aceto G; Pagnotta S; Ruffolo G; Cifelli P; Marini F; Ripoli C; Palma E; Grassi C; Di Domenico F; Perluigi M; Barone E
Antioxidants (Basel); 2023 Jan; 12(1):. PubMed ID: 36670973
[TBL] [Abstract][Full Text] [Related]
15. [Copper accumulation in the brain of Down syndrome model mice and its pathophysiological significance].
Ishihara K; Kawashita E; Akiba S
Nihon Yakurigaku Zasshi; 2019; 154(6):335-339. PubMed ID: 31787686
[TBL] [Abstract][Full Text] [Related]
16. Integrated Quantitative Transcriptome Maps of Human Trisomy 21 Tissues and Cells.
Pelleri MC; Cattani C; Vitale L; Antonaros F; Strippoli P; Locatelli C; Cocchi G; Piovesan A; Caracausi M
Front Genet; 2018; 9():125. PubMed ID: 29740474
[TBL] [Abstract][Full Text] [Related]
17. One-carbon pathway metabolites are altered in the plasma of subjects with Down syndrome: Relation to chromosomal dosage.
Vione B; Ramacieri G; Zavaroni G; Piano A; La Rocca G; Caracausi M; Vitale L; Piovesan A; Gori C; Pirazzoli GL; Strippoli P; Cocchi G; Corvaglia L; Locatelli C; Pelleri MC; Antonaros F
Front Med (Lausanne); 2022; 9():1006891. PubMed ID: 36530924
[TBL] [Abstract][Full Text] [Related]
18. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease.
Blázquez E; Velázquez E; Hurtado-Carneiro V; Ruiz-Albusac JM
Front Endocrinol (Lausanne); 2014; 5():161. PubMed ID: 25346723
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics for mitochondrial dysfunction-linked diseases in Down syndrome.
Ganguly BB; Kadam NN
Mitochondrion; 2023 Jan; 68():25-43. PubMed ID: 36371073
[TBL] [Abstract][Full Text] [Related]
20. Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes.
Lourenco MV; Ferreira ST; De Felice FG
Prog Neurobiol; 2015 Jun; 129():37-57. PubMed ID: 25857551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
